Fostamatinib

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 379 publications

Impact of Fostamatinib on Inflammatory Biomarkers in Hospitalized Patients With COVID-19.

Impact of Fostamatinib on Inflammatory Biomarkers in Hospitalized Patients With COVID-19.

Journal: Critical care explorations

Published: June 22, 2026

A phase I open label study of fostamatinib, a SYK inhibitor, in patients with lower-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.

A phase I open label study of fostamatinib, a SYK inhibitor, in patients with lower-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.

Journal: Leukemia & lymphoma

Published: March 30, 2026

Successful combination therapy with fostamatinib and romiplostim in refractory immune thrombocytopenia 27 years after onset

Successful combination therapy with fostamatinib and romiplostim in refractory immune thrombocytopenia 27 years after onset

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: March 29, 2026

Real world experiences in the treatment of immune thrombocytopenia over a two-year period.

Real world experiences in the treatment of immune thrombocytopenia over a two-year period.

Journal: Oncology research and treatment

Published: March 19, 2026

Efficacy of fostamatinib add-on for TPO receptor agonist-refractory immune thrombocytopenia

Efficacy of fostamatinib add-on for TPO receptor agonist-refractory immune thrombocytopenia

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: March 04, 2026

Refractory Primary Immune Thrombocytopenia With Bleeding and Thrombosis: A Case Report.

Refractory Primary Immune Thrombocytopenia With Bleeding and Thrombosis: A Case Report.

Journal: The American journal of case reports

Published: February 15, 2026

Multiarm multistage randomised controlled trial of inflammatory signal inhibitors (MATIS) for patients hospitalised with COVID-19 pneumonia during the UK pandemic.

Multiarm multistage randomised controlled trial of inflammatory signal inhibitors (MATIS) for patients hospitalised with COVID-19 pneumonia during the UK pandemic.

Journal: BMJ open

Published: February 05, 2026

A Comparative Analysis of the Efficacy, Safety and Mechanism of Action of Flebogamma DIF, Fostamatinib and Romiplostim in Immune Thrombocytopenia.

A Comparative Analysis of the Efficacy, Safety and Mechanism of Action of Flebogamma DIF, Fostamatinib and Romiplostim in Immune Thrombocytopenia.

Journal: Life (Basel, Switzerland)

Published: January 08, 2026

A Clinician Perspective for a Personalized Approach to Management of Chronic Immune Thrombocytopenia with Targeted Therapies Alone or in Combination.

A Clinician Perspective for a Personalized Approach to Management of Chronic Immune Thrombocytopenia with Targeted Therapies Alone or in Combination.

Journal: Journal of clinical medicine

Published: January 07, 2026

Syk inhibition limits autoimmunity and abnormal B cell phenotype and function in mice with B cell-specific TRAF3 deficiency.

Syk inhibition limits autoimmunity and abnormal B cell phenotype and function in mice with B cell-specific TRAF3 deficiency.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Published: December 19, 2025

Management of autoimmune hemolytic anemia.

Management of autoimmune hemolytic anemia.

Journal: Hematology. American Society of Hematology. Education Program

Published: December 05, 2025

Translational immunothrombosis in autoimmune Heparin-Induced thrombocytopenia: targeting the FcγRIIa-Syk-BTK and complement pathways.

Translational immunothrombosis in autoimmune Heparin-Induced thrombocytopenia: targeting the FcγRIIa-Syk-BTK and complement pathways.

Journal: Clinical and experimental medicine

Published: November 05, 2025

Showing 1-12 of 379

Last Updated: 06/30/2026